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Background: Only a few antitumor drugs inhibit the DNA breakage-reunion 
reaction catalyzed by topoisomerase. One is the camptothecin derivative 
topotecan that has recently been used clinically. Others are the glycosylated 
antibiotic rebeccamycin and its synthetic analog NB-506, which is presently in 
phase I of clinical trials. Unlike the camptothecins, rebeccamycin-type 
compounds bind to DNA. We set out to elucidate the molecular basis of their 
interaction with duplex DNA, with particular emphasis on the role of the 
carbohydrate residue. 
Results: We compared the DNA-binding and topoisomerase-l-inhibition 
activities of two isomers of rebeccamycin that contain a galactose residue 
attached to the indolocarbazole chromophore via an c1 (axial) or a p (equatorial) 
glycosidic linkage. The modification of the stereochemistry of the 
chromophore-sugar linkage results in a marked change of the DNA-binding and 
topoisomerase I poisoning activities. The inverted configuration at the C-l ’ of 
the carbohydrate residue abolishes intercalative binding of the drug to DNA 
thereby drastically reducing the binding affinity. Consequently, the a isomer has 
lost the capacity to induce topoisomerase-l-mediated cleavage of DNA. 
Comparison with the aglycone allowed us to determine the energetic 
contribution of the sugar residue. 
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Conclusions: The optimal interaction of rebeccamycin analogs with DNA is 
controlled to a large extent by the stereochemistry of the sugar residue. The 
results clarify the role of carbohydrates in stereospecific drug-DNA interactions 
and provide valuable information for the rational design of new rebeccamycin- 
type antitumor agents. 
Introduction 
The indolocarbazole family is an important class of glyco- 
sylated antitumor antibiotics. This family can be divided 
into two subgroups depending on the nature of the linkage 
between the carbohydrate residue and the heterocyclic 
chromophore. Compounds with the sugar attached to the 
two indole nitrogens have little or no interaction with 
nucleic acids but strongly inhibit different protein kinases. 
This so called ‘closed’ form is typified by the microbial 
antibiotics staurosporine and K-252a that contain a pyra- 
nosy1 and a furanosyl moiety, respectively (Figure la). 
They both represent very potent inhibitors of protein 
kinase C (PKC) and have marked cytotoxic activities [l]. 
This subgroup also includes the synthetic derivative UCN- 
01 (7-hydroxystaurosporine), which is a promising anti- 
tumor agent presently in phase I of clinical trials [2,3]. A 
vast number of synthetic staurosporine analogs have been 
synthesized with the aim of developing inhibitors that are 
specific for one particular PKC isoenzyme [4]. 
The second subgroup consists of indolocarbazole deriva- 
tives in which the carbohydrate moiety is attached to only 
one indole nitrogen, such as the antibiotics rebeccamycin 
and AT-2433-Al/B1 [S-7]. In contrast to staurosporine, 
rebeccamycin does not inhibit PKC in a cell-free system 
but interacts with DNA. The antitumor activity of rebec- 
camycin is attributed to its capacity to induce topoiso- 
merase-I-dependent DNA-strand breaks [6]. Various 
glycosyl-substituted indolocarbazoles with an open struc- 
ture like rebeccamycin specifically inhibit the DNA super- 
coiling enzyme topoisomerase I in a manner similar to that 
of the antitumor drug camptothecin [S-lo]. The synthetic 
derivatives ED-l 10 and NB-506 shown in Figure lb stabi- 
lize topoisomerase-I-DNA covalent complexes and are 
very potent antitumor drugs [ll-131. Recently, a phase I 
clinical trial with NB-506 has been successfully completed 
[14,15]. There is good reason to believe that this drug or a 
closely related congener will soon take its place as an anti- 
cancer agent. 
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Structure of naturally occurring and synthetic antitumor indolocarbazoles. 
In (a) the drugs have a ‘closed’ structure with the sugar attached to the 
two indole nitrogens. In (b) the carbohydrate is attached to only one 
indole nitrogen and referred to as the ‘open’ structure. (c) The structure 
of the a and 6 anomers of rebeccamycin used in this study. 
For both the closed and the open forms of indolocar- Indolocarbazole derivatives are weakly fluorescent in 
bazoles, it is believed that the sugar unit is an important aqueous solution but in the presence of DNA their fluo- 
contributor to the interaction of the drug with the molecu- rescence emission increases considerably, providing a 
lar target. In the open structures, studies have clearly useful means for accurately determining their DNA- 
shown that the removal of the sugar moiety drastically binding affinities. Fluorescence-titration experiments 
reduces the capacity of the drug to interfere with topoiso- using the aglycone and the cx and p anomers are presented 
merase I [9]. More recently, we have provided direct evi- in Figure 2. The titration midpoints of the curves clearly 
dence that the carbohydrate residue is a key element for differ for each drug, indicating that their binding affinities 
both DNA binding and topoisomerase I inhibition [lo]. vary significantly. Nonlinear least-squares analysis of 
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Log (concentration of DNA, M) chem,strv & eioloq, 
Fluorescence titrations for the interaction of the a anomer (diamonds), 
the 6 anomer (circles) and the aglycone (squares) with calf thymus 
DNA. The concentration of ligand was kept constant at 5 uM and the 
DNA concentration varied between 1 mM and 0.1 uM base pairs. The 
relative fluorescence, 0= F-F,/Fr,-F,, is shown as a function of DNA 
concentration. Curve fitting and determination of binding constants 
(summarized in Table 1) were carried out using nonlinear least- 
squares analysis. 
The exact contribution of the sugar to the DNA inter- 
action, however, is still largely unknown and is the issue 
we addressed here. 
The present study is devoted to the characterization of 
the mode of binding, the affinity and the sequence 
selectivity of two isomeric analogs of rebeccamycin 
that have a galactopyranosyl residue linked to the 
N-methylindolocarbazole aglycone by either an CL or a 
p-N-glycosidic bond (compounds 1 and 2; Figure lc). The 
corresponding aglycone lacking the carbohydrate domain 
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Table 1 
Binding constants and energetics of drug binding to DNA. 
F,‘Fo K/lo“ (M-l) -AG,,, (kcal/mol) -6 logW6log[Na+I -AG,, (kcallmol) -AG, (kcallmol) 
a Isomer 9.5 1.14 5.42 
p Isomer 107 12.6 6.61 
Aglycone 5.6 0.82 5.22 
Binding constant (K) and standard free energy changes (AG& refer 
to solution conditions of 6 mM Na,HPO,, 2 mM NaH,PO, and 1 mM 
Na,EDTA, pH 7.0 at 20°C. The uncertainties in the phma& 
experimental values K were estimated to be 10%. The polyelectrolyte 
0.30 0.72 4.70 
0.33 0.79 6.02 
0.29 0.69 4.53 
contribution to the standard free energy change was calculated from 
the relationship AG,, = (SK) RT In [NaCIl, where SK = 6 
logW6log[Na+I. The thermodynamic free-energy change was 
calculated by difference, AG, = AG,,,-AG,,. 
these titration curves yielded binding constants of 
1.14 x lo4 (M bp)-’ and 12.6 x lo4 (M bp)-r for the a and 
B analogs, respectively. The affinity constant of the B drug 
is 11-fold higher than that of its cx counterpart, a differ- 
ence that represents a significant stereospecificity. The 
binding constant measured for the a anomer is not much 
different from that of the aglycone (Table l), which sug- 
gests that in the equatorial configuration the carbohydrate 
residue has little or no effect on the interaction with 
DNA. Note that the binding constant determined for the 
B analog by fluorescence titration is in good agreement 
with that determined for a related B derivative (with an 
OH group on the nitrogen imide instead of a CH, group) 
by absorption measurements and Scatchard analysis 
(K = 17.5 x lo4 M-l) [16]. 
The analysis of the binding constants as a function of the 
salt concentration confirms that the affinity of the B analog 
is more than one order of magnitude higher than that of 
the a anomer or the aglycone. Double logarithmic plots of 
log K versus the log of the Na+ concentration [ 171 yield 
slopes of approximately -0.3 (SK = 6 log K/6 log [Na+], 
Table l), close to the theoretical value of -0.24 that is pre- 
dicted for the binding of an uncharged intercalator to 
DNA [ 181. This small slope arises from the lengthening of 
the DNA helix caused by intercalation, and the concomi- 
tant alteration of the charge density of the lattice, as dis- 
cussed previously with another uncharged intercalating 
drug, hydroxyrubicin [19]. 
Free energy of drug binding to DNA 
The observed free energy of drug binding (AGobs) was cal- 
culated from the binding constants using the standard 
relationship: 
AG,,,= -RT 1nK (1) 
The observed binding free energy can be partitioned 
into the nonelectrostatic contribution (AGJ and the poly- 
electrolyte contribution (AG,,) by the relationship 
A%bs = AG, + AG,,. The polyelectrolyte contribution to 
AG,,, at a given NaCl concentration is given by the rela- 
tionship [20,21]: 
AG,, = (SK) RT In [Na+] (2) 
The energetic parameters are collected in Table 1. For 
AGp values of about -0.75 (k 0.05) kcal/mol at 
[Na+] = 16 mM were determined for all three drugs, indi- 
cating that they bind to DNA with a slight favorable elec- 
trostatic contribution. The nonpolyelectrolyte portion is 
the larger contribution, however, indicating that the 
drug-DNA complexes are stabilized primarily by mol- 
ecular interactions such as hydrogen bonding and van der 
Waals interactions. 
Molecular modeling 
Computational analysis was performed on the compara- 
tive complexation energies of the a and B isomers with 
two B-form DNA hexanucleotides d(CGCGCG), and 
d(CGTGCG)*(CGCACG). Both DNA fragments contain 
CG and/or TG steps that provide appropriate drug- 
binding sites (see the footprinting data below). The 
j3 anomer was found to form a very stable and stereo- 
chemically feasible intercalation complex with both 
hexanucleotides. In contrast, attempts to build an inter- 
calation complex with the ~1 anomer resulted in a highly 
distorted DNA duplex. The chromophore of the interca- 
lated j3 compound remains planar, whereas one of the 
rings of the intercalated a compound is out of the plane 
of the rest of the rings due to the steric properties of the 
sugar molecule. The energy-minimized intercalation 
model with the p isomer is shown in Figure 3. 
DNA-binding mode 
Previous biochemical and spectroscopic studies with dif- 
ferent series of rebeccamycin analogs indicated that the 
planar indolocarbazole chromophore can intercalate into 
DNA [lo]. Evidence that intercalation does occur for the 
B isomer comes from the fluorescence energy-transfer 
experiments shown in Figure 4. Contact energy transfer 
measures the energy transferred from the DNA bases to 
excite an intercalated fluorophore. No such energy trans- 
fer is possible for a groove- or surface-bound fluorophore 
because both the transfer distance and the orientation of 
the donor-acceptor dipoles are unfavorable [Z&23]. The 
method has been used to provide evidence for or against 
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Figure 3 Figure 4 
The view from the minor groove of an energy-minimized model of the 
complex between the p anomer and the hexanucleotide 
d(CGCGCG),. The molecular model illustrates the intercalation of the 
planar indolocarbazole chromophore and the location of the 
carbohydrate in the minor groove of the double helix. The structures 
included water and counterions (Na+) and have been minimized to 
completion (root mean square < 0.001). 
intercalation for a variety of DNA ligands, including 
ruthenium complexes and ethidium bromide [Z&24]. As 
shown in Figure 4, the p derivative is excited by 
absorbance by DNA bases, providing evidence for inter- 
calation. No such energy transfer occured with the 
0: analog, suggesting that it fails to intercalate into 





. . . 
240 245 250 255 260 266 270 275 260 265 
Wavelength (nm) Chemistry & Biology 
Fluorescence energy transfer from DNA to the bound drug. The relative 
fluorescence quantum yield of bound versus free ligand is shown as a 
function of excitation wavelength for the cx (squares) and p (circles) 
anomers. See equation 5 in the Materials and methods section. 
drug-DNA complexes revealed identical trends. A nega- 
tive reduced dichroism comparable with that measured 
for DNA alone at 260 nm (AA/A = -0.47), was measured 
with the p compound-DNA complex at 320 nm, whereas 
the reduced dichroism was considerably reduced in the 
presence of the a analog (AA/A = -0.12 and -0.48 for the 
a and p anomers, respectively). 
We examined the emission lifetimes of the drug-DNA 
complexes at a single mixing ratio of 0.02 mol druglmol bp. 
The fluorescence decay profiles of the drugs were bi-expo- 
nential in the presence of calf thymus DNA or with the 
free drug in aqueous buffer (suggesting that there are two 
distinct emitting species), whereas in dimethyl sulfoxide 
(DMSO) the decay profiles are mono-exponential. This 
might be a characteristic of the existence of drug-drug 
interactions (stacking interactions have been shown with 
related compounds) [ZS]. The extrapolated fluorescence 
lifetimes of the short-lived and long-lived components are 
listed in Table 2 together with their respective intensities. 
The different behaviors of DNA-bound cx isomer and 
p isomer are quite obvious. The results are consistent with 
the steady-state data. The substantial lengthening of the 
fluorescence lifetimes for the p isomer in the presence of 
DNA is consistent with an intercalative binding of the 
indolocarbazole fluorophore. 
Reactivity with chemical probes 
Intercalation of a drug into DNA requires the double helix 
to extend and unwind to accommodate the ligand mol- 
ecules between the base pairs, whereas groove binding or 
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Table 2 Figure 5 
Fluorescence emission lifetimes of the drugs in the absence 
and presence of DNA. 
T, (ns) r2 (ns) f I f 2 z, (ns) 
Aglycone 
DMSO 17.7 
Buffer 4.94 0.32 0.89 0.11 4.43 
+DNA 4.46 2.23 0.49 0.51 3.33 
a Isomer 
DMSO 15.2 
Buffer 3.48 0.44 0.76 0.24 2.76 
+DNA 3.97 0.96 0.86 0.14 3.56 
p Isomer 
DMSO 16.3 
Buffer 5.00 0.54 0.55 0.45 3.00 
+DNA 6.83 1.11 0.93 0.07 6.40 
Average fluorescence lifetime, za= [(f, x z,) + (f,x Ql/(f, + fJ. 
external stacking induces much less (if any) change in the 
DNA structure. If  the p drug effectively intercalates into 
DNA it would be predicted to measurably distort the 
DNA structure, whereas the 0: isomer should have little 
effect. One way of detecting the drug-induced structural 
changes is through the sensitivity of the DNA to chemical 
probes. Accordingly, we have examined the reactivity of a 
“‘P-labeled DNA fragment to,wards two complementary 
probes, diethylpyrocarbonate and potassium perman- 
ganate, that react with purine (A>G) and pyrimidine 
(T>>C) residues, respectively [26]. The DNA hardly 
reacts at all with KMnO, in the absence of the drug, 
whereas in the presence of the a isomer, numerous 
thymine residues are rendered hyper-reactive to the 
probe. The KMnO, hyper-reactive thymidines are dis- 
persed all over the entire DNA fragment, both proximal 
and distal to the preferred binding sites identified by 
footprinting (see below). This suggests that the drug- 
induced structural changes are distributed over several 
nucleotide residues around the intercalation site; such an 
effect has been reported for many intercalating drugs. By 
contrast, there is no ligand-induced hypersensitivity of 
the DNA towards KMnO, in the presence of the 
a isomer. Similar results were obtained using diethylpy- 
rocarbonate (data not shown). The data indicate that the 
a and p anomers exert different effects on DNA struc- 
ture, which reinforces the conclusion that the nature of 
the glycosidic bond is crucial for the interaction with 
DNA. It is conceivable that the specific effect of the 
a anomer on DNA structure contributes to the mecha- 
nism by which the drug inhibits topoisomerase I. 
DNase I footprinting with the 117-mer Pvull-EcoRI restriction fragment 
of plasmid pBS in the presence of the drugs at the indicated 
concentration (pM). The DNA was 3’.end labeled at the EcoRl site with 
[a-32P]dATP in the presence of AMV reverse transcriptase. The 
products of nuclease digestion were resolved on an 8% 
polyacrylamide gel containing 7M urea. Control tracks (0) contained 
no drug. Guanine-specific sequence markers obtained by treatment of 
the DNA with dimethylsulfate followed by piperidine were run in the 
lane marked G. Numbers on the right side of the gel refer to the 
standard numbering scheme for the nucleotide sequence of the DNA 
fragment. The sequence of a preferential binding site for the 8 anomer 
is indicated on the left-hand side. 
Sequence-selective binding 
Footprinting experiments were performed to investigate 
the nucleotide sequence selectivity of the drugs. Figure 5 
shows an autoradiogram resulting from the DNase I 
cleavage of a 3’-end-labeled 117 base pair EcoRI-PvzlII 
restriction fragment from plasmid PBS in the absence and 
presence of the test drugs. The p isomer alters the 
DNAase I cleavage profile, whereas the a isomer and the 
aglycone have no effect. The major sequence protected 
by the p isomer from cleavage by DNase I corresponds to 
5’-GCCAGG between positions 68 and 73. In addition, 
the drug increases the susceptibility to DNase I cleavage 
at A-T-rich sequences (e.g. around nucleotide position 
65, 5’-TTTT-3’). Additional footprinting experiments 
were performed with three other DNA fragments to 
assess the sequence selectivity of the tested compounds 
with respect to a wide variety of potential binding sites. 
In each case, we detected footprints exclusively with the 
p isomer, at sequences such as 5’-AGTGAGTCG-3’ and 
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with the corresponding a anomer. The binding of the 
p compound to GC sequences is therefore favoured over 
binding to A*T or to mixed sequences. We have recently 
reported similar results using another series of rebecca- 
mycin analogs [16]. 
Topoisomerase I poisoning 
Two complementary biochemical assays were performed 
to compare the capacity of the indolocarbazole drugs to 
inhibit topoisomerase I. First we studied DNA relaxation. 
Negatively supercoiled plasmid PAT was incubated with 
both human topoisomerase I and the test drug at 30 yM. 
The DNA samples were treated with sodium dodecylsul- 
fate (SDS) and proteinase K to remove any covalently 
bound protein and were then resolved in a 1% agarose gel. 
The gel shown in Figure 6 indicates that the p isomer 
inhibits the relaxation of DNA mediated by topoiso- 
merase I, whereas both the O! isomer and the aglycone 
have little or no effect. 
The inhibition of DNA relaxation observed with the 
p isomer can arise from stabilization of topoisomerase 
I-DNA cleavable complexes or it can be a result of satu- 
rating the DNA and preventing the enzyme from binding 
to the plasmid. The latter nonspecific effect due to tem- 
plate binding is known to be important with DNA-inter- 
calating agents. This compound can also function as a 
specific topoisomerase I inhibitor, however, trapping the 
cleavable complexes. To examine further the activity of 
the drug on the enzyme, the topoisomerase cleavage sites 
induced by the drugs were mapped using a 160 base pair 
DNA fragment. The EcoRI-AvaI restriction fragment 
from plasmid PAT was uniquely end-labeled at the 
3’-end of the lower strand at the EcoRI site and used as a 
Figure 6 
Supercoiled - 
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Inhibition of topoisomerase-l-mediated DNA supercoiling in the 
presence of the drugs. Native supercoiled PAT DNA (0.5 pg; lane DNA) 
was incubated for 30 min at 37°C with 2 units of topoisomerase I in the 
absence (lane Topol) or in the presence of test drug at 30 FM. The 
reaction was stopped with SDS and treatment with proteinase K. The 
DNA was analyzed by native agarose gel electrophoresis. The gels 
were stained with ethidium bromide and photographed under UV light. 
substrate for the topoisomerase-I-cleavage reaction. The 
cleavage products were analyzed on a sequencing poly- 
acrylamide gel (Figure 7). It can be seen unambiguously 
that the p isomer (and the reference topoisomerase I 
inhibitor camptothecin), but not the cx isomer, strongly 
promote DNA cleavage by human topoisomerase I. 
Although in several cases the cleavage occurs principally 
at sites that have a thymine and a guanine on the 5’ and 3’ 
sides of the cleaved bond, respectively (see [lo] for a sta- 
tistical analysis of the cleavage specificity), it is clear that 
cutting can sometimes occur at different nucleotide posi- 
tions. These data indicate that the b-AT-glycosydic linkage 
represents a key element for topoisomerase I inhibition, 
as well as for DNA intercalation as mentioned above. 
Discussion 
Results obtained using a multifaceted experimental 
approach show clear contrasting behavior between rebec- 
camycin analog stereoisomers. The p compound exhibits a 
high affinity for DNA and forms intercalation complexes. 
It binds selectively to GC-rich sequences in DNA and is a 
potent inhibitor of topoisomerase I. The a anomer, in con- 
trast, binds more weakly to DNA than does the p com- 
pound, does not intercalate and does not inhibit 
topoisomerase I. We conclude that altering the stereo- 
chemistry of the sugar attachment changes the mode of 
binding of the anomer to DNA and the capacity of the 
drug to interfere with topoisomerase I. 
The binding free energy contribution from the carbohy- 
drate can be estimated from the difference in the binding 
free energy of the p glycoside (AG,$ and the aglycone 
(4gl\ume)’ q+%,hc”“e = -1.6 kcal/mol. This value is 
close ;o that calculated for the difference between the 
p and a glycosides, AAGp, = -1.4 kcal/mol. The lack of 
significant difference between the P-glycoside and the 
aglycone in terms of binding free energy suggests that 
the a sugar plays little or no part in the interaction of the 
drug with DNA. (We note that in computing these differ- 
ences in free energy changes, we neglect possible 
entropic contributions to an interaction free energy term 
that formally must be included in the difference.) These 
free energy differences show clearly that the p carbohy- 
drate makes a significant contribution to the binding free 
energy. The p anomer binding free energy is about 
1.4-1.6 kcal/mol more favorable than that observed with 
the a anomer or with the aglycone, most probably 
because of the formation of favorable noncovalent mol- 
ecular interactions between the carbohydrate and the 
DNA. The molecular model shown in Figure 3 is consis- 
tent with this idea. The energetics data demonstrate 
unambiguously that the drug-DNA interaction process is 
stereospecific with respect to the carbohydrate linkage. 
The energetic contribution of the carbohydrate moiety of 
the anthracycline antibiotics [19,27] provides an interesting 
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Phosphorimage comparing the susceptibility of the 160 base pair 
tyrT fragment to cutting by topoisomerase I in the presence of the 
two anomeric compounds. The 5’.end-labeled fragment was 
incubated in the absence (lane Topol) or presence of the 
indolocarbazole derivatives or camptothecin (25 pM each) for 45 min 
at 37°C. Reactions were stopped with SDS and treatment with 
proteinase K. Topoisomerase-l-cleavage reactions were analyzed on 
an 8% denaturing polyacrylamide gel as described in the Materials 
and methods section. Numbers to the left of the gel show the 
nucleotide position, determined with reference to the purine 
nucleotide tracks labeled G+A. The positions of the cleavage sites 
promoted by the 8 anomer are indicated by arrows with the 
corresponding sequences. 
comparison to the data reported here. Doxorubicin, the 
prototype anthracycline, contains the carbohydrate 
daunosamine, which is positively charged at physiological 
pH and which can make a favorable free-energy contribu- 
tion of up to 4 kcal/mol to the overall binding free energy 
from the polyelectrolyte (AG,,) effect alone [28]. Under 
the same salt concentrations as used in the present study, 
AG,, was found to be -2.6 kcal/mol for doxorubicin. In 
contrast, the rebeccamycin compounds studied here lack 
such a large polyelectrolyte contribution because they are 
uncharged, reflected in the modest values of AG,, reported 
in Table 1. The daunosamine, however, contributes an 
additional favorable free-energy increment of about 
-2 kcal/mol, above and beyond its polyelectrolyte contribu- 
tion [27]. This contribution reflects the favorable molecu- 
lar interactions from fitting the daunosamine into the 
minor groove, resulting in van der Waals attractions and 
possible hydrogen-bonding interaction between the amine 
group and DNA bases. The magnitude of this part of the 
daunosamine energetic contribution is comparable to the 
value of AGg-AGaglvcone = -1.6 kcal/mol that was estimated 
for rebeccamycin, which probably reflects similar favorable 
molecular interactions of the carbohydrate moiety in the 
minor groove. Finally, there is a very interesting contrast 
between doxorubicin and rebeccamycin stereoisomers with 
respect to their contributions to DN.A-binding free energy. 
For rebeccamycin, the energetic difference between the p 
and a isomers is essentially the same as that observed 
between the b isomer and the aglycone. In contrast, the b 
anomer of doxorubicin bound to DNA with considerably 
less affinity than the aglycone, indicating a steric penalty 
for incorrect positioning of the carbohydrate moiety [27]. 
For doxorubicin binding to DNA, it is energetically more 
favorable to lack daunosamine than to have it in the wrong 
orientation. This is not the case for the stereoisomers 
of rebeccamycin. 
The rebeccamycin isomers described here are not the 
only anticancer agents that require a glycosyl residue for 
their mechanism of action. Many antitumor drugs 
contain a saccharide domain that contributes signifi- 
cantly to their interactions with DNA [29,30]. One well- 
known case is that of the enediyne family of 
DNA-cleaving antitumor antibiotics. The aryltetrasac- 
charide moiety of calicheamycin y,I, for example, plays a 
critical role in the sequence-selective recognition of 
tetranucleotide sequences such as TCCT, TCTC or 
TTTT, in addition to contributing positively to the 
DNA-cleavage activity of the antibiotic [31-351. The 
carbohydrate portion of calicheamycin not only reads the 
minor-groove sequence but most importantly it orients 
the reactive enediyne aglycone, placing the proradical 
center adjacent to the cleavage site. A similar warhead 
alignment mediated by the oligosaccharide moiety 
occurs with the related drug esperamicin A, [36]. More- 
over, the glycosyl domain of calicheamycin is essential 
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for the inhibition of transcription by polymerase II, Instrumentation 
probably by inducing a conformational change in DNA Absorbance spectra were recorded on a Cary 3E UVlVis spectropho- 
structure [37,38]. With neocarzinostatin, another diyene 
tometer equipped with a thermoelectric temperature controller. Fluo- 
antibiotic, the aminoglycoside residue is not a major 
rescence measurements were done with an ISS Inc. Greg 200 
fluorometer, operated in a steady-state, photon-counting mode. Fluo- 
determinant of base specificity of DNA cleavage but rescence lifetimes were measured using an ISS Inc. K2 multi-frequency 
plays a major functional role in improving the rate and phase fluorometer. 
efficiency of DNA cleavage [39]. Many other drugs 
including the bleomycins, the pluramycins and the aure- 
olic acids (e.g. mithramycin, chromomycin and 
Determination of binding constants by fluorescence titration 
experiments 
Stock solutions of compounds were freshly prepared at a concentra- 
olivomycin) possess DNA-interacting carbohydrate tion of 2 mM in DMSO, and diluted into buffer solution at the desired 
domains. With the aminoglycoside antibiotics such as concentrafion. Calf thymus DNA was purchased from Pharmacia (Lot 
tobramycin and neomycin, molecular recognition of a 
No. 27-4562-02) and was sonicated and purified as described previ- 
defined RNA conformation depends entirely on the 
ously [19]. Before further use, the DNA was dialyzed in the appropriate 
buffer for 24 h, and its concentration was determined by UV absorption 
structure of the saccharide 1401. With daunomvcin. hieh- at 260 nm using a molar extinction coefficient, &,,= 12,824 cm-‘M-l. 
resolution nuclear magnetic- resonance (GMR, &d Titration experiments were carried out in a buffG”consisting of 6 mM 
crystal structural studies show that the sugar residue par- Na,HPO,, 2 mM NaH,PO,, 1 mM Na,EDTA, pH 7.0, unless noted oth- 
ticipates in specific hydrogen-bonding interactions with 
erwise. Fluorescence titration data were recorded at room temperature, 
with excitation at 320 nm and fluorescence emission was monitored 
DNA bases, along with numerous van der Waals interac- over the range of 340-620 nm. For titration experiments, each sample 
tions with atoms in the minor groove [41-43]. was prepareb separately at a constant drug concentration of 5 PM, and 
DNA concentrations ranging from 0.1 pM to 1 mM base pair. 
The pronounced differences between the DNA-binding 
and toposisomerase-I-inhibition activities of the CC and 
Fluorescence titration data were fit directly to get binding constants, 
using a fitting function incorporated into the program FitAll (MTR Soft- 
p isomers of the indolocarbazole analogs described here ware, Toronto). The observed fluorescence is assumed to be a sum of 
represent another example of the key role played by car- the weighted concentrations of free and bound ligand: 
bohydrates in the molecular recognition of DNA. 
F = F” (C,-CJ + FbC, (3) 
Significance where F IS the apparent fluorescence at each DNA concentration, F” is 
Rebeccamycin and its indolocarbazole analogs are the fluorescence intensity of free ligand, and Fb is the fluorescence 
promising antitumor agents, and two synthetic derivatives 
intensity of the bound species. C, and C, are the molar concentrations 
NB-506 and ED-749 are currently in clinical trials for 
or total and bound ligand, respectively. For the interaction of a ligand D 
with a DNA site S, it can be easily shown that: 
potential use in cancer chemotherapy. The cytotoxicity of 
these molecules depends on their capacity to interact with 
DNA and to inhibit topoisomerase I. The rational design 
of rebeccamycin analogs requires, therefore, a precise 
understanding of the molecular rules governing the recog- 
nition of DNA and/or DNA-topoisomerase I complexes 
by the drugs. Our present study has clarified the role of 
the, carbohydrate portion of the drug in its interaction with 
the DNA double helix. The p+a inversion of the coniigu- 
ration of the sugar-indolocarbazole linkage considerably 
reduces the affinity of the drug for DNA, and impedes its 
capacity to form intercalation complexes and to inhibit 
topoisomerase I. The results reveal that the interaction of 
rebeccamycin analogs with DNA is controlled to a large 
extent by the sugar residue and that the isomery of the gly- 
cosidic linkage is essential. The drug-DNA interaction 
process is stereospecific. As such, the results expand our 
knowledge of drug-DNA interactions and provide invalu- 
able information for the design of rebeccamycin-type anti- 
tumor agents. 
Kx2-x(KS, + KD, + 1) + KS,D, = 0 (4) 
Where x = C,, K is the association constant, So is the total site concen- 
tration and D, is the total ligand concentration. Equation 4 is readily 
solved using the quadratic formula. Data in the form of fluorescence 
response F as a function of total DNA site concentration at fixed con- 
centration of ligand may then be fit by nonlinear least-squares methods 
to get K, F” and Fb. 
Fluorescence contact energy transfer 
Contact energy transfer from DNA bases to ligand was measured from 
corrected excitation spectra recorded from 240 nm to 350 nm at 1 nm 
intervals [241. The ratio between the quantum yield of bound ligand 
with excitation in the UV spectral region (a,) to that at 310 nm (Oslo) 
was calculated from the exoression: 
(5) 
where I and E are the measured fluorescence intensities and molar 
extinction coefficient, respecfively. The subscripts b and f refer to the 
bound and free forms of the ligand. The wavelength 310 nm was 
chosen for normalization because of the negligible absorbance of DNA 
in that region of the spectrum. Excitation spectra were corrected for 
inner filter effects prior to normalization. Materials and methods 
Drugs 
The synthesis of the drugs has been reported previously [441. Stock 
solutions of the cc and p isomers were freshly prepared at a concen- 
tration of 2 mM in DMSO, and diluted into buffer solution at the 
desired concentration. 
Molecular-modeling studies 
Molecular modeling using the programs Dlscover and INSIGHT II (Moi- 
ecular Simulations, Inc.) were performed on the CI, p and aglycone 
analogs of rebeccamycin. Drug structures were constructed using the 
Research Paper Topoisomerase I inhibition by rebeccamycin Bailly et a/. 285 
BUILDER program of INSIGHT II. Charge distribution and energy mini- 
mized structures were obtained using the program MOPAC (MNDO) 
and the conjugate-gradient minimization algorithm. Duplex B-DNA 
structures of sequences d(CGCGCG), and d(CGTGCG)* 
(CGCACG) were constructed using the BIOPOLYMER program of 
INSIGHT II. Counterions (sodium atoms) were added at a distance of 
2.5 A from each phosphate to these duplex DNAs. Ligands were man- 
ually docked within the central 5’-CpG-3’ or 5’-TpG-3’ steps of the 
oligonucleotides to minimize close contacts between the ligand and 
DNA. Insertion of the ligand between these base pairs effectively 
opened the intercalation site to accommodate the DNA-binding ligand. 
Periodic boundary conditions were imposed on the ligand-DNA 
complex with an additional 3.5A space added to all sides of the 
complex. The solvation routine of INSIGHT II was then used to add 
water molecules to the ligand-DNA duplex structure. Atomic poten- 
tials were added to all atoms of the assembly using the AMBER force- 
field. The hydrated ligand-DNA complex was then subjected to energy 
minimization under periodic boundary conditions using 1000 steepest- 
descent iterations to reduce the maximum root mean squared (rms) 
derivative to less than 0.5, followed by 10,000 iterations using the con- 
jugate-gradient method to reduce the maximum rms derivative to less 
than 0.001. A distance-dependent dielectric constant of 1 .O was used 
for these calculations. Computations were performed on a Silicon 
Graphics Indigo Elan workstation and visualized using INSIGHT II. 
DNA purification and labeling 
The plasmid pBS (Stratagene, La Jolla, California) was isolated from 
Escherichia co/i by a standard SDS-sodium hydroxide lysis proce- 
dure and purified using Qiagen columns. The purified plasmid was 
then precipitated and resuspended in appropriate buffered medium 
prior to digestion by the restriction enzymes. The two PBS DNA frag- 
ments were prepared by 3’-[32P]-end labeling of the EcoRI-Pvull 
double digest of the plasmid using m[32Pl-dATP and avian myeblasto- 
sis virus (AMV) reverse transcriptase. The digestion products were 
separated on a 6% polyacrylamide gel under native conditions in TBE 
buffered solution (89 mM Tris-borate pH 8.3, 1 mM EDTA). After 
autoradiography, the band of DNA was excised, crushed and soaked 
in water overnight at 37°C. This suspension was filtered through a Mil- 
lipore 0.22 km filter and the DNA was precipitated with ethanol. Fol- 
lowing washing with 70% ethanl>I and vacuum drying of the 
precipitate, the labeled DNA was resuspended in 10 mM Tris adjusted 
to pH 7.0 containing 10 mM NaCI. 
Footprinting experiments 
Samples (3 ~1) of the 32P-labeled DNA fragment were incubated with 
5 pl of the buffer solution containins the desired drug concentration. 
After 20 min incubation at 37°C to ensure equilibration of the binding 
reaction, the digestion was initiated by the addition of 2 pl of DNase I 
(0.01 unit ml-’ enzyme in 20 mM NaCI, 2 mM MgCI,, 2 mM MnCI,, 
pH 7.3). At the end of the reaction time (routinely 4 min at room tem- 
perature), the digestion was stopped by freeze-drying. After lyophiliza- 
tion each sample was resuspended in 4 ~1 of an 80% formamide 
solution containing tracking dyes prior to electrophoresis. 
Topoisomerase I inhibition 
Relaxation assay. Supercoiled pKMp27 DNA (0.5 pg) was incubated 
with 3 units human topoisomerase I (TopoGen Inc, Columbus, Ohio) 
at 37’C for 1 h in relaxation buffer (50 mM Tris pH 7.8, 50 mM KCI, 
10 mM MgCI,, 1 mM dithiothreitol, I mM EDTA) in the presence of 
the drug under study at the indicated concentration. Reactions were 
terminated by addition of SDS and proteinase K. DNA samples were 
then added to the electrophoresis dye mixture (3 ml) and elec- 
trophoresed (35V cm-l) in a 1% agarose gel at room temperature for 
15 h. Gels were stained with ethidium bromide (1 mg ml-‘), washed 
and photographed under UV light. 
Sequencing of topoisomerase-I-media’iated DNA cleavage sites. Each 
reaction mixture contained 2 pl of 3’-end 13*P] labeled DNA (-1 FM), 
5 ~1 of water, 2 pi of 1 Ox topoisomerase I buffer, 10 pl of drug solution 
at the desired concentration (50 pg ml-l). After at least 30 min incuba- 
tion to ensure equilibration, the reaction was initiated by addition of 10 
units topoisomerase I. Samples were incubated for 40 min at 37°C 
prior to adding SDS to 0.25% and proteinase K to 250 pg ml-’ to dis- 
sociate the drug-DNA-topoisomerase-I cleavable complexes. The 
DNA was precipitated with ethanol and then resuspended in 5 ml for- 
mamide-TBE loading buffer, denatured at 90°C for 4 min then chilled 
on ice for 4 min prior to loading onto the sequencing gel. 
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